©TheCanadian Journal ofUrology™: International Supplement, April 2014
56
Practical guide to immunotherapy incastration resistantprostatecancer: theuseof sipuleucel-T immunotherapy
13.PontariMA, RuggieriMR.Mechanisms inprostatitis/chronic
pelvicpain syndrome.
JUrol
2008;179(5Suppl):S61-S71.
14.HroudaD,DalgleishAG.Gene therapy forprostatecancer.
Gene
Ther
1996;3(10):845-852.
15.MadanRA,GulleyJL,KantoffPW.Demystifyingimmunotherapy
inprostatecancer:understandingcurrentand future treatment
strategies.
Cancer J
2013;19(1):50-58.
16.EssajeeS,KaufmanHL. Poxvirusvaccines for cancer andHIV
therapy.
ExpertOpinBiol Ther
2004;4(4):575-588.
17.Gomella LG, MastrangeloMJ, McCue PA et al. Phase I study
of intravesical vaccinia virus as a vector for gene therapy of
bladder cancer.
JUrol
2001;166(4):1291-1295.
18.SmallEJ,SacksN,Nemunaitis Jetal.Granulocytemacrophage
colony-stimulating factor-secreting allogeneic cellular
immunotherapy for hormone-refractory prostate cancer.
Clin
CancerRes
2007;13(13):3883-3891.
19.Hodi FS, O’Day SJ, McDermott DF et al. Improved survival
with ipilimumab inpatientswithmetastaticmelanoma.
NEngl
JMed
2010;363(8):711-723.
20.Brahmer JR, Tykodi SS, ChowLQ et al. Safety and activity of
anti-PD-L1antibody inpatientswithadvanced cancer.
NEngl
JMed
2012;366(26):2455-2465.
21.SmallEJ,SchellhammerPF,HiganoCSetal.Placebo-controlled
phase III trial of immunologic therapy with sipuleucel-T
APC8015 inpatientswithmetastatic, asymptomatic hormone
refractoryprostate cancer.
JClinOncol
2006;24(19):3089-3094.
22.Vacchelli E, Vitale I, EggermontAet al. Trialwatch: Dendritic
cell-based interventions for cancer therapy.
Oncoimmunology
2013;2(10):e25771. Epub 2013 Jul 29.
23.NesslingerNJ,NgA, TsangKYet al.Aviral vaccine encoding
prostate-specific antigen induces antigen spreading to a
common set of self-proteins in prostate cancer patients.
ClinCancerRes
2010;16(15):4046-4056.
24.Gulley JL, Drake CG. Immunotherapy for prostate cancer:
recentadvances, lessons learned,andareas for furtherresearch.
ClinCancerRes
2011;17(12):3884-3891.
25.HainesAM,LarkinSE,RichardsonAPetal.Anovelhybridoma
antibody PASE/4LJ to human prostatic acid phosphatase
suitable for immunohistochemistry.
Br J Cancer
1989;60(6):
887-892.
26.Goldstein NS. Immunophenotypic characterization of 225
prostate adenocarcinomaswith intermediate or highGleason
scores.
Am JClinPathol
2002;117(3):471-477.
27.PeshwaMV,Shi JD,RueggCetal. Inductionofprostate tumor-
specificCD8+ cytotoxicT-lymphocytes invitrousing antigen-
presentingcellspulsedwithprostaticacidphosphatasepeptide.
Prostate
1998;36(2):129-138.
28. JubinskyPT,LaurieAS,NathanDGetal.Expressionandfunction
of the human granulocyte-macrophage colony-stimulating
factor receptor alpha subunit.
Blood
1994;84(12):4174-4185.
29.Ackerman AL, Cresswell P. Cellular mechanisms governing
cross-presentationofexogenousantigens.
NatImmunol
2004;5(7):
678-684.
30.Higano CS, Schellhammer PF, Small EJ et al. Integrated data
from 2 randomized, double-blind, placebo-controlled, phase
3 trials of active cellular immunotherapywith sipuleucel-T in
advancedprostate cancer.
Cancer
2009;115(16):3670-3679.
31.Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary
critique of sipuleucel-T as immunotherapy in castration-
resistant prostate cancer.
J Natl Cancer Inst
2012;104(4):
273-279.
32.Drake CG. Re: interdisciplinary critique of sipuleucel-T as
immunotherapy in castration-resistant prostate cancer.
J Natl
Cancer Inst
2012;104(18):1422, author reply 1422-1423.
33.Gulley JL,LeitmanSF,DahutW,Schlom J.Re: interdisciplinary
critique of sipuleucel-T as immunotherapy in castration-
resistant prostate cancer.
J Natl Cancer Inst
2012;104(14):1106,
author reply 1109-1112.
34.GomellaLG,NabhanC,Whitmore JB,FrohlichMW,GeorgeDJ.
Post-progression treatment with APC8015F may have
prolongedsurvivalofsubjects in thecontrolarmofsipuleucel-T
phase III studies. ASCO 2011 Chicago, IL.
J Clin Oncol
2011;
29(suppl):abstract 4534.
35.SchellhammerPF,ChodakG,Whitmore JBetal.Lowerbaseline
prostate-specific antigen is associated with a greater overall
survival benefit from sipuleucel-T in the Immunotherapy for
Prostate Adenocarcinoma Treatment IMPACT trial.
Urology
2013;81(6):1297-1302.
36.Yu EY, Miller K, Nelson J et al. Detection of previously
unidentifiedmetastaticdiseaseasa leading causeof screening
failure inaphaseIII trialofzibotentanversusplacebo inpatients
withnonmetastatic, castration resistant prostate cancer.
JUrol
2012;188(1):103-109.
37.Flanigan RC, Polcari AJ, Shore ND et al. An analysis of
leukapheresis and central venous catheter use in the
randomized, placebo controlled, phase 3 IMPACT trial of
Sipuleucel-T for metastatic castrate resistant prostate cancer.
JUrol
2013;189(2):521-526.
38.DrakeCG.Prostatecancerasamodelfortumourimmunotherapy.
NatRev Immunol
2010;10(8):580-593.
39.GulleyJL,DrakeCG. Immunotherapyforprostatecancer: recent
advances, lessons learned, and areas for further research.
Clin
CancerRes
2011;17(12):3884-3891.
40.Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel-T
immune parameters correlate with survival: An analysis
of the randomized phase 3 clinical trials in men with
castration-resistantprostatecancer.
Cancer Immunol Immunother
2013;62(1):137-147.
41.Quinn DI, Vaishampayan U, Higano CS et al. Sequencing
therapy in advanced prostate cancer: focus on sipuleucel-T.
ExpertRevAnticancerTher
2014;14(1):51-61.
